OKUR
OnKure Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.58
+0.56%Aug 13, 2026, 00:00 UTC
OnKure Therapeutics repriced outstanding stock options for its CEO, CMO, and CFO to $4.14 per share, effective August 7, 2026, subject to an 18-month retention requirement.
Jun 4, 2026, 00:00 UTC
OnKure Therapeutics, Inc. elected R. Michael Carruthers, Valerie M. Jansen, M.D., Ph.D., and Edward T. Mathers as Class II directors, effective June 3, 2026.